OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 700 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... July 30, 2024 El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 Mapping Cancer Genomic Evolution Offers Insights into Tumor Development March 6, 2020 Load more HOT NEWS News digest – ovarian cancer blood test, statins, spending review and... Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... The Winter Solstice Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile...
